Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer

  • Authors:
    • Shinro Hata
    • Takeo Nomura
    • Kazunori Iwasaki
    • Ryuta Sato
    • Mutsushi Yamasaki
    • Fuminori Sato
    • Hiromitsu Mimata
  • View Affiliations

  • Published online on: May 24, 2017     https://doi.org/10.3892/or.2017.5669
  • Pages: 120-128
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional protein, playing roles in glucose and lipid metabolism, inflammation, angiogenesis, and tumorigenesis. Recent research suggests that ANGPTL4 is induced by hypoxia and is a useful diagnostic or prognostic marker for various cancers. However, it remains unclear whether ANGPTL4 expression influences prostate cancer. Here we examined the biological and clinical relevance of ANGPTL4 expression in prostate cancer. Firstly we examined ANGPTL4 expression in the prostate cancer cell lines LNCaP and LNCaP/CH incubated at 1% O2 for at least 6 months. We compared cellular proliferation, migration, and ANGPTL4 secretion in a culture medium between these cell lines. In addition, we investigated the effect of various concentrations of recombinant ANGPTL4 protein (rANGPTL4) on cellular proliferation and intracellular signaling pathways. Moreover, we used ANGPTL4 knockdown by RNA interference to investigate the influence of ANGPTL4 expression on these cell lines. Finally, we investigated the correlation between ANGPTL4 expression in prostate cancer specimens and clinicopathological parameters using immunohistochemistry. Our data suggested that the expression of ANGPTL4 in hypoxic conditions was 14.4-fold higher than that in normoxic condition. ANGPTL4 secretion in the culture medium increased 7.0-fold. In addition, rANGPTL4 increased cellular proliferation 1.72-fold via Akt activation. Moreover, ANGPTL4 knockdown decreased cell growth and its secretion by 25.7 and 41.4%, respectively, compared with the control. A multivariate analysis showed that positive ANGPTL4 expression in the resected specimens was an independent prognostic indicator of biochemical recurrence (P=0.03, hazard ratio = 2.02). Our results show that ANGPTL4 is induced by hypoxia and promotes cancer progression via the activated PI3K/Akt pathway. Moreover, ANGPTL4 can be used as a prognostic marker for prostate cancer patients undergoing radical prostatectomy.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 38 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hata S, Nomura T, Iwasaki K, Sato R, Yamasaki M, Sato F and Mimata H: Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer. Oncol Rep 38: 120-128, 2017
APA
Hata, S., Nomura, T., Iwasaki, K., Sato, R., Yamasaki, M., Sato, F., & Mimata, H. (2017). Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer. Oncology Reports, 38, 120-128. https://doi.org/10.3892/or.2017.5669
MLA
Hata, S., Nomura, T., Iwasaki, K., Sato, R., Yamasaki, M., Sato, F., Mimata, H."Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer". Oncology Reports 38.1 (2017): 120-128.
Chicago
Hata, S., Nomura, T., Iwasaki, K., Sato, R., Yamasaki, M., Sato, F., Mimata, H."Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer". Oncology Reports 38, no. 1 (2017): 120-128. https://doi.org/10.3892/or.2017.5669